tirzepatide bpi labs challenges patent, cites DiMarchi's work | Sabina Hemmi posted on the topic May 18, 2026: FDA warns

However, as with oral glutathione, we do not have the required amount or quality of research to deem IV glutathione safe for skin lighting in the pregnant, nursing, or even non-pregnant or non-nursing population

Self-Reported Testing (If Any) Most low-cost vendors rely on supplier-issued certificates rather than independent third-party verification

The form documents patient understanding of medication risks, confirms eligibility criteria (such as BMI threshold and age), captures absolute contraindications that would prevent treatment, and verifies identity through document upload to prevent prescription fraud

This protects the medication from heat and light, both of which can break down peptide-based drugs

Then a second study came out in the Lancet that contradicted the NEJM findings